Studies have demonstrated that PDL1 + T cells have various tolerogenic effects on tumor immunity through different mechanisms, including induced STAT3-dependent ‘back-signaling’ in CD4 + T cells, inhibition of effector T cells via the PDL1-PD1 axis, and engagement with PD1 + macrophages [53]. The gene discussed is CD4; the disease is neoplasm.